Key result
In patients with chronic stable angina, isosorbide-5-mononitrate and nifedipine showed no significant difference in anginal attacks over 4 weeks of treatment.
Why the study?
Does isosorbide-5-mononitrate compared to nifedipine reduce anginal attacks in patients with chronic stable angina pectoris?
RCT (n=126)
Open-label
crossover
Yes
Does isosorbide-5-mononitrate compared to nifedipine reduce anginal attacks in patients with chronic stable angina pectoris?
Isosorbide-5-mononitrate and nifedipine provide similar clinical efficacy and safety for the prophylactic treatment of chronic stable angina pectoris.
Answers are grounded in this paper and cite their sources.
Either agent may be selected for stable angina prophylaxis based on patient factors; confirms comparable short-term efficacy in this RCT.
A total of 126 patients from general practice with chronic stable angina pectoris entered the treatment phase of this open, randomized, crossover comparison of 20 mg isosorbide-5-mononitrate, and 20 mg nifedipine. Both treatments were given orally, three times daily, for 4 weeks and sublingual administration of glyceryl trinitrate was allowed throughout. Over the whole treatment period, there was no statistically significant difference between treatments for anginal attacks. However, significantly fewer glyceryl trinitrate tablets were required by patients receiving prophylaxis with nifedipine, although this difference was too small to be of clinical significance. No statistical difference existed between treatments in respect of scores for 'overall intensity of pain', 'physical exercise ability' and 'general well-being'. Of those patients who expressed a preference, the majority preferred the second treatment with no statistically significant difference between isosorbide-5-mononitrate and nifedipine. Both treatments showed similar levels of adverse events, the major difference (not significant) being for flushing of the skin which occurred in five patients given nifedipine compared with one patient given isosorbide-5-mononitrate. It is concluded that, in clinical terms, the two treatments were similar. Headache and dizziness/giddiness were the most frequently recorded adverse events.
No takes yet. Share an insight, caveat, or question.
Ankier et al. (1989) conducted an RCT in chronic stable angina pectoris (n=126). Isosorbide-5-mononitrate vs. Nifedipine 20 mg orally, three times daily was evaluated on anginal attacks. In patients with chronic stable angina, isosorbide-5-mononitrate and nifedipine showed no significant difference in anginal attacks over 4 weeks of treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: